Vaccine Adjuvants Market Size, Share, Trend Forecast 2021
According to research the global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=152603894
Don’t miss out on business opportunities in Vaccine Adjuvants Market
Browse and in-depth TOC on "Vaccine Adjuvants Market"
90 - Tables
42 - Figures
156 - Pages
Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.
The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
Read More Report @ https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html
SEPPIC (France) held the second position in the vaccine adjuvants market in 2015. This can be attributed to the company’s strong portfolio of vaccine adjuvants. The company adopts organic growth strategies such as expansions to boost its market share. For instance, SEPPIC (France) launched a production and sterile packaging unit for vaccine adjuvants and injectables by investing USD 6.66 million in Castres, France.
On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period. This market is mainly driven by factors such as rising prevalence of diseases such as allergy, cancer, and HIV/AIDS; growing demand for advanced treatment options, and development of improved vaccine immunization.
On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Factors such as the rapidly growing geriatric population and vaccines for improved immunization are propelling the growth of this market. Rise in collaborations and acquisitions by private organizations and increased funding by government bodies for research and development are also expected to drive market growth.
On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.